Last reviewed · How we verify
Lidocaine 2% without vessel constrictor
At a glance
| Generic name | Lidocaine 2% without vessel constrictor |
|---|---|
| Also known as | onabotulinum toxin |
| Sponsor | Liaquat National Hospital & Medical College |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Lidocaine in Reducing Opioids Requirement in Day Care Surgery (PHASE3)
- Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections (PHASE4)
- Effectiveness and Safety of Lidocaine for Scleroderma (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: